Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.

BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ...

Shares of Praxis Precision Medicines, Inc. PRAX were down 78.1% on Monday after the company announced disappointing data from the phase II/III Aria study that evaluated its pipeline candidate ...

Tuesday, Praxis Precision Medicines Inc . (NASDAQ:PRAX) shares received a boost as Truist Securities increased its price target for the company to $175 from $150, while maintaining a Buy rating.

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ...

Following a negative phase II/III study of an investigational treatment for major depressive disorder, Praxis Precision Medicines Inc. is dropping staff from the payroll and refocusing the company’s ...

On Wednesday, Needham maintained a Buy rating on shares of Praxis Precision Medicines Inc. (NASDAQ: PRAX) and increased the price target to $151 from $145. The adjustment follows Praxis's recent ...

Praxis Precision Medicines, Inc. PRAX shares surged 23.1% after the clinical-stage biopharmaceutical company reported positive results from its mid-stage study evaluating PRAX-628 in epilepsy patients ...